We are analyzing https://link.springer.com/article/10.1007/s10741-010-9208-0.

Title:
Enhancing the metabolic substrate: PPAR-alpha agonists in heart failure | Heart Failure Reviews
Description:
The prognosis for patients diagnosed with heart failure has significantly improved over the past three decades; however, the disease still confers a high degree of morbidity and mortality. Current treatments for chronic heart failure have focused primarily on blocking neurohormonal signaling and optimizing hemodynamic parameters. Although significant resources have been devoted toward the development of new pharmaceutical therapies for heart failure, few new drugs have been designed to target myocardial metabolic pathways despite growing evidence that on a fundamental level chronic heart failure can be characterized as an imbalance between myocardial energy demand and supply. Disruptions in myocardial energy pathways are evident as the myocardium is unable to generate sufficient amounts of ATP with advancing stages of heart failure. Down-regulation of fatty acid oxidation likely contributes to the phenotype of the “energy starved” heart. Fibrates are small molecule agonists of PPARα pathways that have been used to treat dyslipidemia. Although never used therapeutically in clinical heart failure, PPARα agonists have been shown to enhance fatty acid oxidation, improve endothelial cell function, and decrease myocardial fibrosis and hypertrophy in animal models of heart failure. In light of their excellent clinical safety profile, PPARα agonists may improve outcomes in patients suffering from systolic heart failure by augmenting myocardial ATP production in addition to targeting maladaptive hypertrophic pathways.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Health & Fitness
Fitness & Wellness
Education

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We're unsure if the website is profiting.

Some websites aren't about earning revenue; they're built to connect communities or raise awareness. There are numerous motivations behind creating websites. This might be one of them. Link.springer.com could be secretly minting cash, but we can't detect the process.

Keywords {🔍}

google, scholar, article, cas, heart, pubmed, failure, peroxisome, myocardial, proliferatoractivated, cardiac, metabolism, metabolic, patients, fatty, acid, circulation, oxidation, alpha, pparalpha, receptor, trial, effects, glucose, disease, chronic, med, physiol, res, expression, receptoralpha, fenofibrate, clinical, cardiomyopathy, cardiovascular, study, cardiol, pharmacol, diabetes, stanley, rat, pathways, treatment, activation, cardiovasc, privacy, cookies, content, substrate, agonists,

Topics {✒️}

peroxisome proliferator-activated receptor-alpha peroxisome-proliferator-activated receptor alpha peroxisome proliferator-activated receptor-isoforms stress-activated kinase-dependent mechanisms month download article/chapter glucose fatty-acid cycle peroxisome proliferator-activated receptors peroxisome proliferators-activated receptors pressure-overloaded rat hearts porcine tachycardia-induced cardiomyopathy pacing-induced heart failure dietery medium-chain triglyerides long-term fenofibrate therapy redox-regulated transcription factors transcription factors nf-kappa satyam sarma fatty acid oxidation potassium-insulin-glucose solution post-ischaemic functional loss high-density lipoprotein cholesterol chronic pressure overload myocardial substrate metabolism myocardial carbohydrate metabolism alter myocardial metabolism article sarma retinoid × receptor-α american heart association ppar-alpha agonists full article pdf high-fat feeding fatty acids de silva ds ppar-alpha agonist failing human heart cardiac malonyl-coa levels left ventricular dysfunction 9-cis retinoic acid myocardial energy pathways privacy choices/manage cookies clinical heart failure congestive heart failure decompensated heart failure glucose metabolism idiopathic dilated cardiomyopathy author correspondence mice lacking pparalpha long term survival chronic heart failure cardiac phenotype induced increasing glucose transport

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Enhancing the metabolic substrate: PPAR-alpha agonists in heart failure
         description:The prognosis for patients diagnosed with heart failure has significantly improved over the past three decades; however, the disease still confers a high degree of morbidity and mortality. Current treatments for chronic heart failure have focused primarily on blocking neurohormonal signaling and optimizing hemodynamic parameters. Although significant resources have been devoted toward the development of new pharmaceutical therapies for heart failure, few new drugs have been designed to target myocardial metabolic pathways despite growing evidence that on a fundamental level chronic heart failure can be characterized as an imbalance between myocardial energy demand and supply. Disruptions in myocardial energy pathways are evident as the myocardium is unable to generate sufficient amounts of ATP with advancing stages of heart failure. Down-regulation of fatty acid oxidation likely contributes to the phenotype of the “energy starved” heart. Fibrates are small molecule agonists of PPARα pathways that have been used to treat dyslipidemia. Although never used therapeutically in clinical heart failure, PPARα agonists have been shown to enhance fatty acid oxidation, improve endothelial cell function, and decrease myocardial fibrosis and hypertrophy in animal models of heart failure. In light of their excellent clinical safety profile, PPARα agonists may improve outcomes in patients suffering from systolic heart failure by augmenting myocardial ATP production in addition to targeting maladaptive hypertrophic pathways.
         datePublished:2010-11-23T00:00:00Z
         dateModified:2010-11-23T00:00:00Z
         pageStart:35
         pageEnd:43
         sameAs:https://doi.org/10.1007/s10741-010-9208-0
         keywords:
            PPAR alpha
            Heart failure
            Myocardial metabolism
            Fatty acid metabolism
            Glucose metabolism
            Cardiology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10741-010-9208-0/MediaObjects/10741_2010_9208_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10741-010-9208-0/MediaObjects/10741_2010_9208_Fig2_HTML.gif
         isPartOf:
            name:Heart Failure Reviews
            issn:
               1573-7322
               1382-4147
            volumeNumber:17
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer US
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Satyam Sarma
               affiliation:
                     name:Northwestern University
                     address:
                        name:Division of Cardiology, Department of Medicine, Northwestern Memorial Hospital, Northwestern University, Chicago, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Hossein Ardehali
               affiliation:
                     name:Northwestern University
                     address:
                        name:Division of Cardiology, Department of Medicine, Northwestern Memorial Hospital, Northwestern University, Chicago, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Mihai Gheorghiade
               affiliation:
                     name:Northwestern University
                     address:
                        name:Center for Cardiovascular Innovation, Northwestern Memorial Hospital, Northwestern University, Chicago, USA
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Enhancing the metabolic substrate: PPAR-alpha agonists in heart failure
      description:The prognosis for patients diagnosed with heart failure has significantly improved over the past three decades; however, the disease still confers a high degree of morbidity and mortality. Current treatments for chronic heart failure have focused primarily on blocking neurohormonal signaling and optimizing hemodynamic parameters. Although significant resources have been devoted toward the development of new pharmaceutical therapies for heart failure, few new drugs have been designed to target myocardial metabolic pathways despite growing evidence that on a fundamental level chronic heart failure can be characterized as an imbalance between myocardial energy demand and supply. Disruptions in myocardial energy pathways are evident as the myocardium is unable to generate sufficient amounts of ATP with advancing stages of heart failure. Down-regulation of fatty acid oxidation likely contributes to the phenotype of the “energy starved” heart. Fibrates are small molecule agonists of PPARα pathways that have been used to treat dyslipidemia. Although never used therapeutically in clinical heart failure, PPARα agonists have been shown to enhance fatty acid oxidation, improve endothelial cell function, and decrease myocardial fibrosis and hypertrophy in animal models of heart failure. In light of their excellent clinical safety profile, PPARα agonists may improve outcomes in patients suffering from systolic heart failure by augmenting myocardial ATP production in addition to targeting maladaptive hypertrophic pathways.
      datePublished:2010-11-23T00:00:00Z
      dateModified:2010-11-23T00:00:00Z
      pageStart:35
      pageEnd:43
      sameAs:https://doi.org/10.1007/s10741-010-9208-0
      keywords:
         PPAR alpha
         Heart failure
         Myocardial metabolism
         Fatty acid metabolism
         Glucose metabolism
         Cardiology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10741-010-9208-0/MediaObjects/10741_2010_9208_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10741-010-9208-0/MediaObjects/10741_2010_9208_Fig2_HTML.gif
      isPartOf:
         name:Heart Failure Reviews
         issn:
            1573-7322
            1382-4147
         volumeNumber:17
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer US
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Satyam Sarma
            affiliation:
                  name:Northwestern University
                  address:
                     name:Division of Cardiology, Department of Medicine, Northwestern Memorial Hospital, Northwestern University, Chicago, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Hossein Ardehali
            affiliation:
                  name:Northwestern University
                  address:
                     name:Division of Cardiology, Department of Medicine, Northwestern Memorial Hospital, Northwestern University, Chicago, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Mihai Gheorghiade
            affiliation:
                  name:Northwestern University
                  address:
                     name:Center for Cardiovascular Innovation, Northwestern Memorial Hospital, Northwestern University, Chicago, USA
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Heart Failure Reviews
      issn:
         1573-7322
         1382-4147
      volumeNumber:17
Organization:
      name:Springer US
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Northwestern University
      address:
         name:Division of Cardiology, Department of Medicine, Northwestern Memorial Hospital, Northwestern University, Chicago, USA
         type:PostalAddress
      name:Northwestern University
      address:
         name:Division of Cardiology, Department of Medicine, Northwestern Memorial Hospital, Northwestern University, Chicago, USA
         type:PostalAddress
      name:Northwestern University
      address:
         name:Center for Cardiovascular Innovation, Northwestern Memorial Hospital, Northwestern University, Chicago, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Satyam Sarma
      affiliation:
            name:Northwestern University
            address:
               name:Division of Cardiology, Department of Medicine, Northwestern Memorial Hospital, Northwestern University, Chicago, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Hossein Ardehali
      affiliation:
            name:Northwestern University
            address:
               name:Division of Cardiology, Department of Medicine, Northwestern Memorial Hospital, Northwestern University, Chicago, USA
               type:PostalAddress
            type:Organization
      name:Mihai Gheorghiade
      affiliation:
            name:Northwestern University
            address:
               name:Center for Cardiovascular Innovation, Northwestern Memorial Hospital, Northwestern University, Chicago, USA
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Division of Cardiology, Department of Medicine, Northwestern Memorial Hospital, Northwestern University, Chicago, USA
      name:Division of Cardiology, Department of Medicine, Northwestern Memorial Hospital, Northwestern University, Chicago, USA
      name:Center for Cardiovascular Innovation, Northwestern Memorial Hospital, Northwestern University, Chicago, USA
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(224)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.86s.

LINK . SPRINGER . COM {}